Clinical Trials Logo
  1. Home
  2. Vaccine
  3. NCT05161845

Clinical Trial of Measles, Mumps and Rubella Combined Vaccine, Live

Vaccine Clinical Trial

Official title:
A Phase IV Randomized, Blinded Clinical Trial to Assess Measles Mumps and Rubella Combined Vaccine, Live, (MMR) Lot-to-lot Consistency in Healthy Chinese Children at the Age of 8-12 Months

Clinical Trial Summary

To evaluate the immunogenicity, lot-to-lot consistency and safety of three consecutive batches of Measles, Mumps and Rubella Combined Vaccine, Live.

Clinical Trial Description

To assess Measles Mumps and Rubella Combined Vaccine, Live, (MMR) lot-to-lot consistency in healthy Chinese Children at the age of 8-12 months, and the participants randomized to receive one injections of 0.5 mL Measles, Mumps and Rubella Combined Vaccine, Live at day 0. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT05161845
Study type Interventional
Source Shanghai Institute Of Biological Products
Contact
Status Completed
Phase Phase 4
Start date December 23, 2021
Completion date October 1, 2022
View Details
See also
  Status Clinical Trial Phase
Recruiting NCT04460235 - Immunogenicity of an Anti-pneumococcal Combined Vaccination in Acute Leukemia or Lymphoma Phase 4
Recruiting NCT04543877 - WHNRC (Western Human Nutrition Research Center) Fiber Intervention Study Early Phase 1
Completed NCT00401505 - Rubella Susceptibility in Multiparous Women
Recruiting NCT05054621 - Immunogenicity of COVID-19 Vaccine on Heterologous Schedule Phase 2
Completed NCT05083065 - Evaluation of Menstrual Irregularities and Abnormal Uterine Bleeding After Covid-19 Vaccine
Recruiting NCT05085145 - Immunogenicity and Safety of COVID-19 Vaccine in People Living With HIV Phase 4
Completed NCT05046548 - This is a Double-blind, Placebo-controlled, Randomized Study of the Tolerability, Safety and Immunogenicity of an Inactivated Whole Virion Concentrated Purified Vaccine (CoviVac) Against Covid-19 Phase 1/Phase 2
Completed NCT01961960 - A Study to Evaluate Intramuscular ASP7374 Phase 3
Completed NCT01961947 - Study of ASP7374, Cell-culture-derived Influenza Vaccine Phase 3
Completed NCT00401700 - Influenza Vaccine Postpartum Questionnaire
Completed NCT03300050 - Safety and Immunogenicity of a Live-attenuated Universal Flu Vaccine Followed by an Inactivated Universal Flu Vaccine Phase 1
Completed NCT01015703 - Open-label Safety and Tolerability Study of CoVaccine HT™ in Healthy Volunteers Phase 1
Completed NCT00560066 - Safety of a Influenza Vaccine Produced Either in Mammalian Cell Culture or in Embryonated Hen Eggs in Adults and Elderly With and Without Underlying Medical Conditions, and Immunogenicity in a Subset of Subjects With Underlying Medical Conditions Phase 4
Active, not recruiting NCT05099965 - Trial to Evaluate the Safety and Immunogenicity of a Modified Vaccinia Ankara (MVA)-Based Anti-Cytomegalovirus (CMV) Vaccine (Triplex®) Phase 2
Recruiting NCT04638985 - Evaluation of Immunogenicity and Safety of Combined Immunization of sIPV, DTaP and MMR Phase 4
Active, not recruiting NCT04741828 - Persistence and Long-Term Protection of Vi Antibodies Induced by Vi-DT Conjugate Vaccines in Indonesian Phase 2/Phase 3
Completed NCT05083039 - Observational Program, Study the Preventive Efficacy of the BiVac Polio Vaccine Against the Incidence of Acute Respiratory Infections, Including COVID-19
Completed NCT03714737 - Immunogenicity and Safety of Bivalent Meningococcal Serogroups A and C Tetanus Toxoid Conjugate Vaccine in Chinese Phase 3
Completed NCT04664309 - Understanding Immunity to the COVID-19 Vaccines
Active, not recruiting NCT05752747 - The Effect of Shotblocker and Cold Massage on Pain, Crying Time and Physiological Parameters in Babies N/A